CALCIUM RECEPTOR ANTAGONISTS

CALCIUM RECEPTOR ANTAGONISTS

wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SHINAGAWA, YUKO, NAKAGAWA, TAKASHI, KATSUSHIMA, TAKEO
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SHINAGAWA, YUKO
NAKAGAWA, TAKASHI
KATSUSHIMA, TAKEO
description wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R are each C1-6 alkyl group and the like; R is optionally substituted aryl group or optionally substituted heteroaryl group; X , X and X are each C1-6 alkylene group and the like; and X and X are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP1308436A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP1308436A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP1308436A43</originalsourceid><addsrcrecordid>eNrjZJBxdvRx9gz1VQhydXYNCPEPUnD0C3F09_fzDA4J5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BhsYGFibGZo4mxkQoAQBAeCCQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CALCIUM RECEPTOR ANTAGONISTS</title><source>esp@cenet</source><creator>SHINAGAWA, YUKO ; NAKAGAWA, TAKASHI ; KATSUSHIMA, TAKEO</creator><creatorcontrib>SHINAGAWA, YUKO ; NAKAGAWA, TAKASHI ; KATSUSHIMA, TAKEO</creatorcontrib><description>wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R are each C1-6 alkyl group and the like; R is optionally substituted aryl group or optionally substituted heteroaryl group; X , X and X are each C1-6 alkylene group and the like; and X and X are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.</description><edition>7</edition><language>eng ; fre ; ger</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051005&amp;DB=EPODOC&amp;CC=EP&amp;NR=1308436A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76292</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051005&amp;DB=EPODOC&amp;CC=EP&amp;NR=1308436A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHINAGAWA, YUKO</creatorcontrib><creatorcontrib>NAKAGAWA, TAKASHI</creatorcontrib><creatorcontrib>KATSUSHIMA, TAKEO</creatorcontrib><title>CALCIUM RECEPTOR ANTAGONISTS</title><description>wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R are each C1-6 alkyl group and the like; R is optionally substituted aryl group or optionally substituted heteroaryl group; X , X and X are each C1-6 alkylene group and the like; and X and X are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJBxdvRx9gz1VQhydXYNCPEPUnD0C3F09_fzDA4J5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BhsYGFibGZo4mxkQoAQBAeCCQ</recordid><startdate>20051005</startdate><enddate>20051005</enddate><creator>SHINAGAWA, YUKO</creator><creator>NAKAGAWA, TAKASHI</creator><creator>KATSUSHIMA, TAKEO</creator><scope>EVB</scope></search><sort><creationdate>20051005</creationdate><title>CALCIUM RECEPTOR ANTAGONISTS</title><author>SHINAGAWA, YUKO ; NAKAGAWA, TAKASHI ; KATSUSHIMA, TAKEO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP1308436A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2005</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>SHINAGAWA, YUKO</creatorcontrib><creatorcontrib>NAKAGAWA, TAKASHI</creatorcontrib><creatorcontrib>KATSUSHIMA, TAKEO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHINAGAWA, YUKO</au><au>NAKAGAWA, TAKASHI</au><au>KATSUSHIMA, TAKEO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CALCIUM RECEPTOR ANTAGONISTS</title><date>2005-10-05</date><risdate>2005</risdate><abstract>wherein R is optionally substituted aryl group or optionally substituted heteroaryl group; R is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R is hydrogen atom, C1-6 alkyl group and the like; R and R are each C1-6 alkyl group and the like; R is optionally substituted aryl group or optionally substituted heteroaryl group; X , X and X are each C1-6 alkylene group and the like; and X and X are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP1308436A4
source esp@cenet
subjects ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title CALCIUM RECEPTOR ANTAGONISTS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T08%3A23%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHINAGAWA,%20YUKO&rft.date=2005-10-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP1308436A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true